Clinical success of anti-infective combination therapy compare to monotherapy in patients with carbapenem-resistant Pseudomonas aeruginosa infection: a 10-years retrospective study

Abstract Background Carbapenem-resistant Pseudomonas aeruginosa (CRPA) infection has become a major public health concern. The recommendations for monotherapy and combination therapy in the current guidelines lack sufficient evidence to support them. The primary objective of this study is to determi...

Full description

Bibliographic Details
Main Authors: Jialong Chen, Jing Lin, Jianzhen Weng, Yang Ju, Yanming Li
Format: Article
Language:English
Published: BMC 2024-02-01
Series:BMC Infectious Diseases
Subjects:
Online Access:https://doi.org/10.1186/s12879-024-09060-2
_version_ 1797275709161340928
author Jialong Chen
Jing Lin
Jianzhen Weng
Yang Ju
Yanming Li
author_facet Jialong Chen
Jing Lin
Jianzhen Weng
Yang Ju
Yanming Li
author_sort Jialong Chen
collection DOAJ
description Abstract Background Carbapenem-resistant Pseudomonas aeruginosa (CRPA) infection has become a major public health concern. The recommendations for monotherapy and combination therapy in the current guidelines lack sufficient evidence to support them. The primary objective of this study is to determine the effectiveness of anti-Infective combination therapy compared to monotherapy in achieving clinical success in patients with CRPA infection and risk factors of clinical failure of monotherapy. Methods A retrospective study from Medical Information Mart for Intensive Care IV (MIMIC-IV) was conducted. We included adults with infections caused by CRPA. The outcomes of this study were clinical success, complete clinical success, and 28-day all-cause mortality. Results A total of 279 subjects were finally enrolled. The rate of clinical success for combination therapy was higher than that for monotherapy (73.1% versus 60.4%, p=0.028). Compared to clinical failure patients, patients in the clinical success group were more likely to die within 28 days after CRPA was found (48.3% versus 3.6%, p<0.001). In a multivariate logistic regression analysis, monotherapy was found to be significantly correlated with clinical success (OR, 0.559, 95% CI, 0.321-0.976; p = 0.041). Conclusion Combination therapy is more effective for CRPA infection patients, especially those whose SOFA score is ≥ 2 or whose Charlson comorbidity index is ≥ 6.
first_indexed 2024-03-07T15:18:24Z
format Article
id doaj.art-c2035137aead46e58a34700fc519f63d
institution Directory Open Access Journal
issn 1471-2334
language English
last_indexed 2024-03-07T15:18:24Z
publishDate 2024-02-01
publisher BMC
record_format Article
series BMC Infectious Diseases
spelling doaj.art-c2035137aead46e58a34700fc519f63d2024-03-05T17:49:04ZengBMCBMC Infectious Diseases1471-23342024-02-0124111010.1186/s12879-024-09060-2Clinical success of anti-infective combination therapy compare to monotherapy in patients with carbapenem-resistant Pseudomonas aeruginosa infection: a 10-years retrospective studyJialong Chen0Jing Lin1Jianzhen Weng2Yang Ju3Yanming Li4Department of Pulmonary and Critical Care Medicine, Beijing Hospital,National Center of Gerontology, the Institute of Geriatric Medicine, Chinese Academy of Medical SciencesGraduate School, Peking Union Medical College, Chinese Academy of Medical SciencesDepartment of Pulmonary and Critical Care Medicine, Beijing Hospital,National Center of Gerontology, the Institute of Geriatric Medicine, Chinese Academy of Medical SciencesDepartment of Pulmonary and Critical Care Medicine, Beijing Hospital,National Center of Gerontology, the Institute of Geriatric Medicine, Chinese Academy of Medical SciencesDepartment of Pulmonary and Critical Care Medicine, Beijing Hospital,National Center of Gerontology, the Institute of Geriatric Medicine, Chinese Academy of Medical SciencesAbstract Background Carbapenem-resistant Pseudomonas aeruginosa (CRPA) infection has become a major public health concern. The recommendations for monotherapy and combination therapy in the current guidelines lack sufficient evidence to support them. The primary objective of this study is to determine the effectiveness of anti-Infective combination therapy compared to monotherapy in achieving clinical success in patients with CRPA infection and risk factors of clinical failure of monotherapy. Methods A retrospective study from Medical Information Mart for Intensive Care IV (MIMIC-IV) was conducted. We included adults with infections caused by CRPA. The outcomes of this study were clinical success, complete clinical success, and 28-day all-cause mortality. Results A total of 279 subjects were finally enrolled. The rate of clinical success for combination therapy was higher than that for monotherapy (73.1% versus 60.4%, p=0.028). Compared to clinical failure patients, patients in the clinical success group were more likely to die within 28 days after CRPA was found (48.3% versus 3.6%, p<0.001). In a multivariate logistic regression analysis, monotherapy was found to be significantly correlated with clinical success (OR, 0.559, 95% CI, 0.321-0.976; p = 0.041). Conclusion Combination therapy is more effective for CRPA infection patients, especially those whose SOFA score is ≥ 2 or whose Charlson comorbidity index is ≥ 6.https://doi.org/10.1186/s12879-024-09060-2MonotherapyCombination therapyCarbapenem-resistant Pseudomonas aeruginosaEffectiveness
spellingShingle Jialong Chen
Jing Lin
Jianzhen Weng
Yang Ju
Yanming Li
Clinical success of anti-infective combination therapy compare to monotherapy in patients with carbapenem-resistant Pseudomonas aeruginosa infection: a 10-years retrospective study
BMC Infectious Diseases
Monotherapy
Combination therapy
Carbapenem-resistant Pseudomonas aeruginosa
Effectiveness
title Clinical success of anti-infective combination therapy compare to monotherapy in patients with carbapenem-resistant Pseudomonas aeruginosa infection: a 10-years retrospective study
title_full Clinical success of anti-infective combination therapy compare to monotherapy in patients with carbapenem-resistant Pseudomonas aeruginosa infection: a 10-years retrospective study
title_fullStr Clinical success of anti-infective combination therapy compare to monotherapy in patients with carbapenem-resistant Pseudomonas aeruginosa infection: a 10-years retrospective study
title_full_unstemmed Clinical success of anti-infective combination therapy compare to monotherapy in patients with carbapenem-resistant Pseudomonas aeruginosa infection: a 10-years retrospective study
title_short Clinical success of anti-infective combination therapy compare to monotherapy in patients with carbapenem-resistant Pseudomonas aeruginosa infection: a 10-years retrospective study
title_sort clinical success of anti infective combination therapy compare to monotherapy in patients with carbapenem resistant pseudomonas aeruginosa infection a 10 years retrospective study
topic Monotherapy
Combination therapy
Carbapenem-resistant Pseudomonas aeruginosa
Effectiveness
url https://doi.org/10.1186/s12879-024-09060-2
work_keys_str_mv AT jialongchen clinicalsuccessofantiinfectivecombinationtherapycomparetomonotherapyinpatientswithcarbapenemresistantpseudomonasaeruginosainfectiona10yearsretrospectivestudy
AT jinglin clinicalsuccessofantiinfectivecombinationtherapycomparetomonotherapyinpatientswithcarbapenemresistantpseudomonasaeruginosainfectiona10yearsretrospectivestudy
AT jianzhenweng clinicalsuccessofantiinfectivecombinationtherapycomparetomonotherapyinpatientswithcarbapenemresistantpseudomonasaeruginosainfectiona10yearsretrospectivestudy
AT yangju clinicalsuccessofantiinfectivecombinationtherapycomparetomonotherapyinpatientswithcarbapenemresistantpseudomonasaeruginosainfectiona10yearsretrospectivestudy
AT yanmingli clinicalsuccessofantiinfectivecombinationtherapycomparetomonotherapyinpatientswithcarbapenemresistantpseudomonasaeruginosainfectiona10yearsretrospectivestudy